These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11745235)
1. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Zhan M; Yu D; Lang A; Li L; Pollock RE Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235 [TBL] [Abstract][Full Text] [Related]
2. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829 [TBL] [Abstract][Full Text] [Related]
3. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. Zhan M; Yu D; Liu J; Glazer RI; Hannay J; Pollock RE J Biol Chem; 2005 Feb; 280(6):4825-33. PubMed ID: 15563462 [TBL] [Abstract][Full Text] [Related]
5. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. Lopes de Menezes DE; Hu Y; Mayer LD J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Lee TK; Lau TC; Ng IO Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756 [TBL] [Abstract][Full Text] [Related]
7. [The effect of p53 gene on p-glycoprotein expression and chemotherapeutic cytotoxicity of hepatocellular carcinoma]. Han Y; Liang L; Huang J; Ming W Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):237-9. PubMed ID: 11602059 [TBL] [Abstract][Full Text] [Related]
8. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
9. Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Qi J; Yang CZ; Wang CY; Wang SB; Yang M; Wang JH Acta Pharmacol Sin; 2002 Jun; 23(6):544-50. PubMed ID: 12060530 [TBL] [Abstract][Full Text] [Related]
10. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
11. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Hua J; Mutch DG; Herzog TJ Gynecol Oncol; 2005 Jul; 98(1):31-8. PubMed ID: 15921732 [TBL] [Abstract][Full Text] [Related]
12. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China. Dong-Dong L; Xi-Ran Z Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194 [TBL] [Abstract][Full Text] [Related]
13. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
14. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro. Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772 [TBL] [Abstract][Full Text] [Related]
15. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Hannay JA; Liu J; Zhu QS; Bolshakov SV; Li L; Pisters PW; Lazar AJ; Yu D; Pollock RE; Lev D Mol Cancer Ther; 2007 May; 6(5):1650-60. PubMed ID: 17513613 [TBL] [Abstract][Full Text] [Related]
16. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells. Ramachandran C; You W; Krishan A Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174 [TBL] [Abstract][Full Text] [Related]
17. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Kong D; Ma S; Liang B; Yi H; Zhao Y; Xin R; Cui L; Jia L; Liu X; Liu X Biomed Pharmacother; 2012 Jun; 66(4):271-8. PubMed ID: 22564245 [TBL] [Abstract][Full Text] [Related]
18. [Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms]. Gai XD; Li GL; Huang JZ; Xue HJ; Wang D Ai Zheng; 2006 Aug; 25(8):954-9. PubMed ID: 16965674 [TBL] [Abstract][Full Text] [Related]
19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822 [TBL] [Abstract][Full Text] [Related]
20. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]